Case Clinical Trials Unit
病例临床试验单位
基本信息
- 批准号:10532725
- 负责人:
- 金额:$ 243.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-02-13 至 2027-11-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS clinical trial groupAIDS preventionAddressAdultAfricaAfricanAnti-Retroviral AgentsAreaBasic ScienceBiopsyCerebrospinal FluidClinicalClinical ManagementClinical ResearchClinical TrialsClinical Trials Cooperative GroupClinical Trials UnitCollaborationsComplementDatabasesDevelopmentDiseaseDoctor of PhilosophyEnrollmentEpidemicEvaluationFacultyFundingGrantHIVHIV AntibodiesHIV InfectionsHIV Vaccine Trials NetworkHIV prevention trialHIV vaccineHIV/TBHealthHepatitisHepatitis C TherapyImmune responseImmunizationImmunocompetenceImmunologic MonitoringImmunologyImmunotherapyInflammationInfrastructureInternationalJointsLaboratoriesLeadershipLeukapheresisLifeLinkLogisticsMetabolicMonitorMonitoring Clinical TrialsNational Institute of Allergy and Infectious DiseaseOrganPET/CT scanPathogenesisPerformancePersonsPharmaceutical PreparationsPhasePopulationPositioning AttributePredispositionPreventionPrevention ResearchProductivityProtocols documentationResearchResearch PersonnelRiskRoleSiteSpecial PopulationTissue SampleTranslational ResearchTuberculosisUgandaUnited States National Institutes of HealthUniversitiesantiretroviral therapyclinical centerclinical infrastructureclinical research siteclinical trial analysisdeterminants of treatment resistanceexpectationexperiencehigh riskimprovedinterestlymph nodesmembernotch proteinnoveloutreach programparticipant enrollmentpreventrecruittargeted treatmenttranslational research programtreatment trialvaccination strategyvaccine responsevaccine trialvolunteer
项目摘要
ABSTRACT
The Case Clinical Trials Unit (CTU) comprises three highly productive clinical research sites: Case/UHC in
Cleveland, the University of Cincinnati, and the Joint Clinical Research Center in Kampala. Each of these
three sites is a top performing ACTG treatment trial site with excellent accruals, outstanding performance
evaluations and major roles in the leadership of the network and it is scientific productivity. A key theme of
this CTU is the close link of our clinical research portfolio with our basic and translational research
programs. Thus, the three CRS sites of the Case CTU bring a comprehensive research plan to the
enterprise. Led by faculty who are national and international leaders in their fields, these units are poised
to make substantive contributions to each of the priority areas targeted by the ACTG: Inflammation/End
Organ Disease, Antiretroviral Medications, HIV Eradication and Cure, Tuberculosis, and Hepatitis. The
Case/UHC CRS has also been a productive member of the HVTN. The Case/UHC CRS has been a high-
performing site in this network, having enrolled participants, including some from difficult-to-reach segments
of the population, into multiple HVTN trials during this funding cycle. In some cases, enrollment has
substantially exceeded expectations from the site. Additionally, Case CTU investigators are highly
accomplished researchers who have extensive experience in the monitoring of immune responses form
immunization, in evaluating diverse immunization strategies to enhance vaccine responsiveness, and in
the use of vaccine responsiveness as a readout of immune competence. The University of Cincinnati CRS
is a highly efficient, well-managed CRS that has been conducting clinical and translational research for the
ACTG since 1987, and is the number 1 site by number of participants enrolled in the US. In addition to their
extraordinary performance on enrollments, the site has extensive accumulated expertise in the metabolic
complications of HIV, and is additionally a high-performing protocol-specific HPTN site. The JCRC is one
of the top-performing international sites in the ACTG, and is the critical component in the contributions of
the Case CTU to the tuberculosis agenda. It is also the site of the first hepatitis C treatment clinical trial in
Africa, the ACTG A5360 protocol. The JCRC CRS has also previously demonstrated its ability to access
large numbers of subjects in well-defined populations at high risk for HIV infection, having been the site of
the first HIV vaccine trial in Africa, and can begin contributing to the HIV prevention networks immediately
as well if selected as a site. Thus, the three CRS that comprise this CTU are positioned to provide sustained
leadership and contribution to the treatment and prevention agenda of the NIAID Networks.
摘要
病例临床试验单位(CTU)由三个高产的临床研究中心组成:
克利夫兰、辛辛那提大学和坎帕拉的联合临床研究中心。这一切成功都
三个研究中心是一个表现最好的ACTG治疗试验中心,具有出色的应计利润,
评价和网络的领导作用,它是科学生产力的主要作用。的一个关键主题
该CTU是我们临床研究组合与我们基础和转化研究的紧密联系
程序.因此,Case CTU的三个CRS站点为全球带来了全面的研究计划
企业.在各自领域的国家和国际领导者的带领下,这些单位已经准备好了
为ACTG针对的每个优先领域做出实质性贡献:炎症/结束
器官疾病,抗逆转录病毒药物,艾滋病毒根除和治疗,结核病和肝炎。的
Case/UHC CRS也是HVTN的一个富有成效的成员。案例/UHC CRS一直很高-
在这个网络中的执行站点,已经招募了参与者,包括一些来自难以到达的部分
在本资助周期内,将人群纳入多项HVTN试验。在某些情况下,
大大超出了网站的预期。另外,反恐组的调查人员
在监测免疫反应方面有丰富经验的有成就的研究人员,
免疫接种,评价各种免疫战略,以提高疫苗的反应,
使用疫苗反应性作为免疫能力的读数。辛辛那提大学CRS
是一个高效,管理良好的CRS,一直在进行临床和转化研究,
ACTG自1987年以来,是美国招募参与者人数最多的研究中心。除了它们
在注册方面的卓越表现,该网站在代谢方面积累了广泛的专业知识,
它是一个高性能的方案特异性HPTN网站。JCRC是一个
ACTG中表现最好的国际网站之一,是贡献的关键组成部分,
把反恐小组的工作转移到结核病议程上它也是第一个丙型肝炎治疗临床试验的地点,
非洲,ACTG A5360协议。JCRC CRS此前也证明了其访问
明确定义的HIV感染高危人群中的大量受试者,
非洲第一个艾滋病毒疫苗试验,并可以立即开始为艾滋病毒预防网络做出贡献
如果被选为网站,也是如此。因此,包括该CTU的三个CRS被定位成提供持续的
领导和促进NIAID网络的治疗和预防议程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY M. JACOBSON其他文献
JEFFREY M. JACOBSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY M. JACOBSON', 18)}}的其他基金
Innate and adaptive defenses against SARS-COV-2 in the oral cavity during acute unvaccinated and breakthrough infections
急性未接种疫苗和突破性感染期间口腔针对 SARS-COV-2 的先天和适应性防御
- 批准号:
10667248 - 财政年份:2022
- 资助金额:
$ 243.64万 - 项目类别:
Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140
使用 CCR5 抗体 PRO 140 进行长效、自我管理的 HIV 治疗
- 批准号:
8541374 - 财政年份:2011
- 资助金额:
$ 243.64万 - 项目类别:
Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140
使用 CCR5 抗体 PRO 140 进行长效、自我管理的 HIV 治疗
- 批准号:
8546145 - 财政年份:2011
- 资助金额:
$ 243.64万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
8215745 - 财政年份:2010
- 资助金额:
$ 243.64万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
9178399 - 财政年份:2010
- 资助金额:
$ 243.64万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
8425102 - 财政年份:2010
- 资助金额:
$ 243.64万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
8603231 - 财政年份:2010
- 资助金额:
$ 243.64万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
8054808 - 财政年份:2010
- 资助金额:
$ 243.64万 - 项目类别:
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140
使用 CCR5 mAb PRO 140 进行 HIV 进入抑制剂治疗
- 批准号:
7575211 - 财政年份:2008
- 资助金额:
$ 243.64万 - 项目类别:
相似海外基金
HIV/AIDS prevention and intervention: HIV surveillance methods, Per-exposure prophylaxis eligibility and HIV/STI testing behaviours among a cohort of people living with HIV.
HIV/艾滋病预防和干预:HIV 感染者群体中的 HIV 监测方法、每次暴露预防资格和 HIV/STI 检测行为。
- 批准号:
495195 - 财政年份:2023
- 资助金额:
$ 243.64万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10013921 - 财政年份:2020
- 资助金额:
$ 243.64万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10181081 - 财政年份:2020
- 资助金额:
$ 243.64万 - 项目类别:
UCLA AIDS Prevention and Treatment Clinical Trials Unit
加州大学洛杉矶分校艾滋病预防和治疗临床试验单位
- 批准号:
10166309 - 财政年份:2020
- 资助金额:
$ 243.64万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10597008 - 财政年份:2020
- 资助金额:
$ 243.64万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10386931 - 财政年份:2020
- 资助金额:
$ 243.64万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
9921510 - 财政年份:2019
- 资助金额:
$ 243.64万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
9753631 - 财政年份:2019
- 资助金额:
$ 243.64万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
10265667 - 财政年份:2019
- 资助金额:
$ 243.64万 - 项目类别:
Closing the Gap: Involving Indigenous Elders and youth in HIV/AIDS prevention using participatory filmmaking
缩小差距:利用参与式电影制作让土著老年人和青年参与艾滋病毒/艾滋病预防工作
- 批准号:
364681 - 财政年份:2017
- 资助金额:
$ 243.64万 - 项目类别: